| 1 |
34972202 | Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. | 2022 Feb 22 |
1 |
| 2 |
33686114 | Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. | 2021 Mar 8 |
1 |
| 3 |
32375399 | Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. | 2020 May 4 |
1 |
| 4 |
32558295 | Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. | 2020 Jul 7 |
1 |
| 5 |
28361959 | Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue. | 2017 Mar 31 |
2 |
| 6 |
26766294 | Overview of CDK9 as a target in cancer research. | 2016 |
1 |
| 7 |
27378523 | Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. | 2016 Jul 5 |
4 |
| 8 |
27486754 | Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. | 2016 Aug 30 |
2 |
| 9 |
25395429 | Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. | 2015 Jan 15 |
1 |
| 10 |
25578475 | CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. | 2015 Jun |
1 |
| 11 |
25882699 | Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. | 2015 Aug |
1 |
| 12 |
25962959 | Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. | 2015 Jun 20 |
1 |
| 13 |
25217392 | Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. | 2014 Nov |
1 |
| 14 |
23053255 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. | 2012 Dec |
1 |